These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 1378674)
1. Clinical and electrophysiologic studies of R61748 (transcainide): a new class Ic antiarrhythmic drug. Yang X; Yu T; Kesteloot H Acta Cardiol; 1992; 47(1):43-56. PubMed ID: 1378674 [TBL] [Abstract][Full Text] [Related]
2. Electrophysiologic, antiarrhythmic and hemodynamic effects of transcainide. Carmeliet E; Janssen PA; Heykants J; Niemegeers CJ; Remeysen P; Van De Water A; Van Gerven W; Wauquier A; Xhonneux R Arch Int Pharmacodyn Ther; 1987 Jun; 287(2):272-90. PubMed ID: 3632145 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and tolerance of the antiarrhythmic agent transcainide (R 54718). Stroobandt R; Bennett PB; Hondeghem LM; Kesteloot H Eur J Clin Pharmacol; 1987; 32(5):449-56. PubMed ID: 2441995 [TBL] [Abstract][Full Text] [Related]
4. Sodium channel block by a potent, new antiarrhythmic agent, transcainide, in guinea pig ventricular myocytes. Bennett PB; Stroobandt R; Kesteloot H; Hondeghem LM J Cardiovasc Pharmacol; 1987 Jun; 9(6):661-7. PubMed ID: 2442531 [TBL] [Abstract][Full Text] [Related]
5. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo. Costard-Jäckle A; Franz MR J Pharmacol Exp Ther; 1989 Oct; 251(1):39-46. PubMed ID: 2795468 [TBL] [Abstract][Full Text] [Related]
6. Effects on transmembrane action potential, slow inward current and force of contraction in ventricular cardiac muscle of BRL 31660, a new antiarrhythmic drug with class I and class IV activity. Brückner R; Schmitz W; Scholz H Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):86-93. PubMed ID: 3839047 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiologic effects of nicainoprol, a putative class I antiarrhythmic agent, on the guinea pig ventricular papillary muscle. Kimura T; Imanishi S; Arita M J Cardiovasc Pharmacol; 1989 May; 13(5):767-73. PubMed ID: 2472526 [TBL] [Abstract][Full Text] [Related]
9. Experimental studies on the antiarrhythmic action of a lidocaine analog. Okuma K; Sugiyama S; Wada M; Sugenoya J; Niimi N Cardiology; 1976; 61(4):289-97. PubMed ID: 65226 [TBL] [Abstract][Full Text] [Related]
10. Electrophysiological effects of ACC-9358, a novel class I antiarrhythmic agent, on isolated canine Purkinje fibers and ventricular muscle. Brown BS J Pharmacol Exp Ther; 1989 Feb; 248(2):552-8. PubMed ID: 2918472 [TBL] [Abstract][Full Text] [Related]
11. Frequency-dependent effects of antiarrhythmic drugs on action potential duration and refractoriness of canine cardiac Purkinje fibers. Nattel S; Zeng FD J Pharmacol Exp Ther; 1984 Apr; 229(1):283-91. PubMed ID: 6707943 [TBL] [Abstract][Full Text] [Related]
12. [Effects of lidocaine and its metabolite, monoethylglycine xylidide (MEGX), on transmembrane action potentials in guinea-pig papillary muscles]. Hiraoka I; Oshita S; Morimoto Y; Ban T Masui; 1990 Feb; 39(2):196-203. PubMed ID: 2325252 [TBL] [Abstract][Full Text] [Related]
13. An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist. Pugsley MK; Saint DA; Hayes ES; Abraham S; Walker MJ Eur J Pharmacol; 2015 Aug; 761():330-40. PubMed ID: 26086860 [TBL] [Abstract][Full Text] [Related]